Premium
CALCIUM ANTAGONISTS AND HYPERTENSION
Author(s) -
Nayler W. G.,
Dillon J. S.,
Sturrock W. J.
Publication year - 1988
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.1988.tb01050.x
Subject(s) - nisoldipine , verapamil , calcium , medicine , endocrinology , blood pressure , pharmacology , chemistry , nifedipine
SUMMARY 1. Calcium antagonists, including verapamil, are now used widely in the management of patients with hypertension. 2. Six weeks of chronic therapy with verapamil (50 mg/kg per day, orally) to produce a plasma level of 80–100 ng/ml in Sprague‐Dawley rats depletes cardiac noradrenaline (NA) without apparently causing β 1 adrenoceptor ‘up’ regulation. 3. The effect of verapamil on cardiac NA is rapidly reversed upon verapamil withdrawal. 4. Chronic therapy with nisoldipine (100 mg/kg per day, orally) had no effect on cardiac NA. 5. Verapamil (50 mg/kg per day, orally) and nisoldipine (100 mg/kg per day, orally) therapy for 6 weeks prevented the time‐dependent increase in systolic blood pressure in SHR rats. 6. Binding studies with (—)[ 3 H]‐D888 (desmethoxyverapamil) indicated that the affinity of the phenylalkylamine binding sites is higher in hearts of SHR relative to hearts from age‐matched (25 weeks) WKY and SD, without any change in density.